Today: October 22, 2016, 1:44 pm

SYMBIO - Significant Upside still Remains: Bendamustine + Regosertib + Cash to In-license More! - new market research report published
SYMBIO - Significant Upside still Remains: Bendamustine + Regosertib + Cash to In-license More! - a new market research report on 2014-03-14 08:47:01
PI3K inhibitors and clinical data of Bendamustine +other drugs in chronic lymphocytic leukemia (CLL) and other leukemias were the flavor at ASH ´12 and at the 31st JP Morgan Healthcare conference. The positive impact of these was seen in the small cap Japanese company SymBio Pharma (4582) whose stock has gone up by ~185% since our initiation on September 14th 2012.

SymBio´s focus on Japan and select Asia Pacific Rim countries market along with its pipeline makes it attractive to companies seeking presence in these geographies. We currently attribute this impact to the investment it received from PE Whiz Partners in the form of convertible bonds and promising future potential of its product portfolio.

For more details, please read our report released on 16th January. 2013 on SymBio titled "Significant Upside still Remains: Bendamustine + Regosertib + Cash to In-license More!"

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 350 Words
Related Articles
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.